Ibio: Of The Current Report On Form 8k It Filed With The Securities And Exchange Commission On April 8, 2026 (the “original Form 8k”) To Correct A Typographical Error Contained Therein Regarding The Date That The Series G Warrants (the “series G Warrants”) To Purchase Up To 35,770,000 Shares Of The Company’s Common Stock, Par Value $0.001 Per Share (the “common Stock”) Will Expire. As Amended, This Amendment No. 1 Correctly States That The Series G Warrants Will Expire At 5:00 P.m. (new York City Time) On May 20, 2026. This Amendment No. 1 Also Updates The Number Of Outstanding Series G Warrants And Adds Disclosure Regarding The Number Of Outstanding Shares Of The Company’s Common Stock And The Issuance Of Prefunded Warrants Upon The Exercise Of Series G Warrants

Show full article

This functionality is available for registred users only

• Full name
  Ibio Inc
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***